Dual immunotherapy with nivolumab and ipilimumab should be the new standard of care for patients with malignant pleural mesothelioma, according to researchers whose trial showed improved overall survival compared to platinum-based chemotherapy. Presented at the International Association for the Study of Lung Cancer (IASLC) Virtual Symposium, the findings from the Checkmate 743 randomised controlled trial ...
First positive results for dual immunotherapy in mesothelioma
By Michael Woodhead
12 Aug 2020